Short Interest in Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) Rises By 7.8%

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 2,500,000 shares, a growth of 7.8% from the December 15th total of 2,320,000 shares. Currently, 8.0% of the shares of the stock are short sold. Based on an average daily volume of 544,200 shares, the short-interest ratio is currently 4.6 days.

In related news, insider Christopher John Morl sold 15,034 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were sold at an average price of $51.38, for a total value of $772,446.92. Also, CFO Thomas Patrick Kelly sold 3,750 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $44.34, for a total transaction of $166,275.00. Insiders sold 295,133 shares of company stock worth $14,891,278 in the last 90 days. 7.02% of the stock is currently owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter valued at $194,000. Man Group plc acquired a new position in shares of Deciphera Pharmaceuticals during the 3rd quarter worth about $1,079,000. Redmile Group LLC lifted its stake in Deciphera Pharmaceuticals by 115.0% in the 3rd quarter. Redmile Group LLC now owns 4,780,898 shares of the company’s stock valued at $162,264,000 after purchasing an additional 2,557,522 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in Deciphera Pharmaceuticals during the third quarter worth approximately $973,000. Finally, Barclays PLC increased its holdings in shares of Deciphera Pharmaceuticals by 250.2% during the third quarter. Barclays PLC now owns 33,548 shares of the company’s stock worth $1,138,000 after purchasing an additional 23,967 shares during the period. Institutional investors own 69.45% of the company’s stock.

DCPH stock traded up $0.75 during mid-day trading on Friday, reaching $67.92. 50,848 shares of the stock traded hands, compared to its average volume of 660,270. Deciphera Pharmaceuticals has a one year low of $19.88 and a one year high of $70.00. The business has a 50-day moving average price of $60.07 and a two-hundred day moving average price of $40.32. The stock has a market capitalization of $3.43 billion, a PE ratio of -24.09 and a beta of 2.03.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings data on Monday, November 4th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.09). As a group, equities analysts anticipate that Deciphera Pharmaceuticals will post -4.11 earnings per share for the current year.

Several equities analysts have recently issued reports on the company. HC Wainwright initiated coverage on Deciphera Pharmaceuticals in a research note on Thursday, October 3rd. They issued a “buy” rating and a $60.00 price objective for the company. JMP Securities reaffirmed a “buy” rating and set a $70.00 target price on shares of Deciphera Pharmaceuticals in a report on Wednesday. SunTrust Banks began coverage on Deciphera Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $77.00 target price on the stock. Piper Jaffray Companies raised their price target on Deciphera Pharmaceuticals from $55.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. Finally, Svb Leerink raised Deciphera Pharmaceuticals from an “underperform” rating to a “market perform” rating and raised their price target for the stock from $29.00 to $34.00 in a report on Tuesday, October 29th. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the stock. Deciphera Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $57.50.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Featured Article: Why is the ex-dividend date different from the record date?

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with's FREE daily email newsletter.